Targeting protein-protein interactions for cancer therapy

Journal of Molecular Medicine

Volumn 83, Issue 12, 2005, Pages 955-963

  Fry, David C ^a   Vassilev, Lyubomir T ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

Cancer; Drug discovery; Protein protein interactions; Therapy

Indexed keywords

ANTIBIOTIC AGENT; ANTIMYCIN A1; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BENZENE DERIVATIVE; BETA CATENIN; BIBENZYL DERIVATIVE; CASPASE; CHELERYTHRINE; CHROMENE DERIVATIVE; CULLIN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; HYPOXIA INDUCIBLE FACTOR 1; ONCOPROTEIN; POLYPHENOL DERIVATIVE; PROTEIN MDM2; PROTEIN P53; RAF PROTEIN; RAS PROTEIN; SMALL MOLECULE INHIBITOR; T CELL FACTOR PROTEIN; TETROCARCIN; THIAZOLIDINE DERIVATIVE; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; BETA SHEET; BINDING AFFINITY; CANCER CELL; CANCER THERAPY; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; COMPLEX FORMATION; DNA REPAIR; DRUG RESEARCH; GENE FUSION; HUMAN; MOLECULAR MIMICRY; NONHUMAN; ONCOGENE; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BINDING SITES; DRUG DESIGN; HUMANS; LIGANDS; MODELS, MOLECULAR; NEOPLASMS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 28544446811     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-005-0705-x     Document Type: Review

References (38)

1. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu E (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844-848
2. Clackson T, Wells JA (1995) A hot spot of binding energy in a hormone-receptor interface. Science 267:383-386
3. Toogood PL (2002) Inhibition of protein-protein association by small molecules: approaches and progress. J Med Chem 45:1543-1558
4. Berg T (2003) Modulation of protein-protein interactions with small organic molecules. Angew Chem Int Ed Engl 42:2462-2481
5. Arkin MR, Wells JA (2004) Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 3:301-317
6. McDowell RS, Blackburn BK, Gadek TR, McGee LR, Rawson T, Reynolds ME, Robarge KD, Somers TC, Thorsett ED, Tischler M, Webb RR, Venuti MC (1994) From peptide to non-peptide. 2. The de novo design of potent, non-peptidal inhibitors of platelet aggregation based on a benzodiazepine scaffold. J Am Chem Soc 116:5077-5083
7. Ku TW, Ali FE, Barton, LS, Bean JW, Bondinell WE, Burgess JL, Callahan JF, Calvo RR, Chen L, Eggleston DS, Gleason JG, Huffman WF, Hwang SM, Jakas DR, Karash CB, Keenan RM, Kopple KD, Miller WH, Newlander KA, Nichols A, Parker MF, Peishoff CE, Samanen JM, Uzinskas I, Venslavsky JW (1993) Direct design of a potent non-peptide fibrinogen receptor antagonist based on the structure and conformation of a highly constrained cyclic RGD peptide. J Am Chem Soc 115:8861-8862
8. Stahl M, Bur D, Schneider G (1999) Mapping of proteinase active sites by projection of surface-derived correlation vectors. J Comput Chem 20:336-347
9. Graham TA, Weaver C, Mao F, Kimelman D, Xu W (2000) Crystal structure of a beta-catenin/Tcf complex. Cell 103:885-896
10. Zheng N, Schulman BA, Song L, Miller JJ, Jeffrey PD, Wang P, Chu C, Koepp DM, Elledge SJ, Pagano M, Conaway RC, Conaway JW, Harper JW, Pavletich NP (2002) Structure of the Cul1-Rbx1-Skp1-F box(Skp2) SCF ubiquitin ligase complex. Nature 416:703-709
11. Emerson SD, Madison VS, Palermo RE, Waugh DS, Scheffler JE, Tsao K-L, Kiefer SE, Liu SP, Fry DC (1995) Solution structure of the ras-binding domain of c-raf-1 and identification of its ras interaction surface. Biochemistry 34:6911-6918
12. Nassar N, Horn G, Herrmann C, Scherer A, McCormick F, Wittinghofer A (1995) The 2.2 angstrom crystal structure of the ras-binding domain of the serine/threonine kinase c-raf-1 in complex with rap-1a and a GTP analog. Nature 375:554-560
13. Zhao X, Ghaffari S, Lodish H, Malashkevich VN, Kim PS (2002) Nat Struct Biol 9:117-120
14. Tong L, Warren TC, King J, Betageri R, Rose J, Jakes S (1996) Crystal structures of the human p561ck SH2 domain in complex with two short phosphotyrosyl peptides at 1.0 A and 1.8 A resolution. J Mol Biol 256:601-610
15. Elia AEH, Rellos P, Haire LF, Chao JW, Ivins FJ, Hoepker K, Mohammad D, Cantley LC, Smerdon SJ, Yaffe MB (2003) The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo Box domain. Cell 115:83-95
16. Chen X, Bhandari R, Vinkemeier U, Van Den Akker F, Darnell JE, Kuriyan J (2003) A reinterpretation of the dimerization interface of the N-terminal domains of Stats. Protein Sci 12:361-365
17. Dames SA, Martinez-Yamout M, De Guzman RN, Dyson HJ, Wright PE (2002) Structural basis for Hif-1alpha/CBP recognition in the cellular hypoxic response. Proc Natl Acad Sci U S A 99:5271-5276
18. Himane JP, Rajashankar KR, Lackman M, Cowan CA, Henkemeyer M, Nikolov DB (2001) Ciystal structure of an Eph receptor-ephrin complex. Nature 414:933-938
19. Rustandi RR, Baldisseri DM, Weber DJ (2000) Solution structure of the C-terminal negative regulatory domain of p53 bound to S100B(Bb). Nat Struct Biol 7:570-574
20. Markowitz J, Chen I, Gitti R, Baldisseri DM, Pan Y, Udan R, Carrier F, MacKerell AD, Weber D (2004) Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction. J Med Chem 47:5085-5093
21. Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M, Yoon HS, Shuker SB, Chang BS, Minn AJ, Thompson CB, Fesik SW (1997) Structure of Bcl-XL-Bak peptide complex: recognition between regulators of apoptosis. Science 275:983-986
22. Kim KM, Giedt CD, Basanez G, O'Neill JW, Hill JJ, Han YH, Tzung SP, Zimmerberg J, Hockenbery DM, Zhang KYJ (2001) Biophysical characterization of recombinant human Bcl-2 and its interactions with an inhibitory ligand. Biochemistry 40:4911-4922
23. Nakashima T, Miura M, Hara M (2000) Tetrocardin A inhibits mitochondrial functions of Bcl-2 and suppresses its anti-apoptotic activity. Cancer Res 60:1229-1235
24. Chan SL, Lee MC, Tan KO, Yang LK, Lee ASY, Flotow H, Fu NY, Butler MS, Soejarto DD, Buss AD, Yu VC (2003) Identification of chelerythrine as an inhibitor of Bcl-XL function. J Biol Chem 278:20453-20456
25. Enyedy IJ, Ling Y, Nacro K, Tomita Y, Wu X, Cao Y, Guo R, Li B, Zhu X, Huang Y, Long YQ, Roller PP, Yang D, Wang S (2001) Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem 44:4313-4324
26. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasa SM, Croce C, Alnemri ES, Huang Z (2000) Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A 97:7124-7129
27. Leone M, Zhai D, Sareth S, Kitada S, Reed JC, Pellecchia M (2003) Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2 family proteins. Cancer Res 63:8118-8121
28. Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T, Yuan J (2001) Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-XL. Nat Cell Biol 3:173-182
29. Yin H, Hamilton AD (2004) Terephthalamide derivatives as mimetics of the helical region of Bak peptide target Bcl-XL protein. Bioorg Med Chem Lett 14:1375-1379
30. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hadjuk P, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng SC, Nimmer PM, O'Connor JM, Oleksijew A, Petro AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumors. Nature 435:677-681
31. Liu Z, Sun C, Olejniczak ET, Meadows RP, Betz SF, Oost T, Herrmann J, Wu JC, Fesik SW (2000) Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 408:1004-1008
32. Sun H, Nikolovska-Coleska Z, Yang CY, Xu L, Liu M, Tomita Y, Pan H, Yoshioka Y, Krajewski K, Roller PP, Wang S (2004) Structure-based design of potent, conformationally constrained Smac mimetics. J Am Chem Soc 126:16686-16687
33. Oost TK, Sun C, Armstrong RC, Al-Assaad A-S, Betz SF, Deckwerth TL, Ding H, Elmore SW, Meadows RP, Olejniczak ET, Oleksijew A, Oltersdorf T, Rosenberg SH, Shoemaker AR, Tomaselli KJ, Zou H, Fesik SW (2004) Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 47:4417-4426
34. Chene P (2003) Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 3:102-109
35. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich N (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274:948-953
36. Fry DC, Graves BJ, Vassilev LT (in press) Exploiting protein-protein interactions to design an activator of p53. In: Protein-protein interactions: a molecular cloning manual. Cold Spring Harbor Laboratory, New York
37. Fry DC, Graves B, Vassilev LT (in press) Development of E3-substrate (MDM2-p53) binding inhibitors: structural aspects. Methods Enzymol
38. Fry DC, Emerson SD, Palme S, Vu BT, Liu C-M, Podlaski F (2004) NMR structure of a complex between MDM2 and a small molecule inhibitor. J Biomol NMR 30:163-173